PMC3921806_01
Metastatic lesion before (A, B) and seven cycles after (C, D) the start of gemcitabine-interferon-a therapy.
CEJU-65-00200-g001.jpg
PMC3921806_01_CEJU-65-00200-g001.jpg
F0001
Two months after the dose increase, progression of the lung metastases was recognized (Fig. 1a, b). A CT scan performed after seven cycles of GI therapy showed nearly 80% shrinkage compared with the baseline tumor measurements (Fig. 1c, d).
Metastatic lesion before (A) and two cycles after (B), and 12 cycles after (C, D) the start of sunitinib therapy.
CEJU-65-00200-g002.jpg
PMC3921806_01_CEJU-65-00200-g002.jpg
F0002
In June 2009, follow-up CT scan revealed local recurrence in the renal fossa (Fig. 2a, b). Sunitinib was continued; CT scan after twelve cycles of therapy showed CR compared with the baseline tumor measurements (Fig. 2c, d).